ArticleJournal of inflammation research2025
Successful Treatment of Severe and Refractory Eosinophilic Pustular Folliculitis with Dupilumab: A Case Report with Two-Year Relapse-Free Follow-Up.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eosinophilic pustular folliculitis (EPF) is a rare chronic inflammatory skin disease characterized by eosinophilic infiltration and recurrent sterile pustules. Current treatments are often ineffective, and the disease frequently relapses. Methods: We report a case of a 71-year-old female with severe EPF and a 17-year history of recurrent pruritic papulopustular eruptions. Dupilumab was administered subcutaneously with a 600 mg loading dose followed by 300 mg every two weeks over two treatment courses, separated by a five-month loss to follow-up. Results: After dupilumab therapy, the patient's skin lesions completely resolved, accompanied by a marked decrease in peripheral eosinophil counts. During a 2-year follow-up, no recurrence was observed. Conclusion: Dupilumab demonstrated significant efficacy and safety in this severe and refractory EPF case, resulting in long-term remission without relapse, and highlighting its potential as a novel treatment option for EPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.